COVID-19 GWAS Results - For Public Use
This site compiles COVID-19 genetic scan results for immediate public download and use from any source permitting such use. Users may cite this resource by referencing the HGG Advances publication Thibord et al. 2022. Right click links provided here and select “open link in a new tab” to stay on this webpage.
Format changes: 1) some variants have scientific format POS, i.e. 1.2e+07 for 12000000, now changed to integer, 2) 01, 02,…, 09 in CHR, now changed to 1, 2,.., 9. Changes are made from 01/04/2021 release.
Prior to 07/14/2020: The use of the term “positive” below denotes a positive or assumed positive COVID-19 case based on study definitions. “Negative” indicates someone who has tested negative or presumed negative based on study definitions for COVID-19. “Unknown” indicates population control samples who may not have been tested or may not yet have results.
Between 07/14/2020 and 09/08/2020: COVID-19 deaths (ICD 10 U071) or inpatient diagnosis of COVID-19 (ICD 10 U071) were also added to “positive”. When new death data are released by UK BioBank, six COVID-19 death GWAS will be conducted in addition to COVID-19 GWAS.
From 10/16/2020 and on: COVID-19 deaths (ICD 10 U071), inpatient diagnosis of COVID-19 (ICD 10 U071), primary care clinical data indicating COVID-19 (both TPP/CTV3 and EMIS/SNOMED CT coding systems – see below) were also added to “positive”.
COVID-19 in TPP/CTV3 coding system (01/31/2020 or later)
Y228d: Coronavirus disease 19 caused by severe acute respiratory syndrome coronavirus 2 confirmed by laboratory test (situation)
Y20d1: Severe acute respiratory syndrome coronavirus 2 detected (finding)
Y20fa: Coronavirus disease 19 caused by severe acute respiratory syndrome coronavirus 2 (disorder)
Y210a: Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (disorder)
Y210b: Infection of upper respiratory tract caused by severe acute respiratory syndrome coronavirus 2 (disorder)
Y210e: Detection of severe acute respiratory syndrome coronavirus 2 using polymerase chain reaction technique (procedure)
Y23f7: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) detection result positive
COVID-19 in EMIS/SNOMED CT coding system (01/31/2020 or later)
EMISNQCO303: 2019-nCoV (Wuhan) infection
186747009: Coronavirus infection (disorder)
12802201000006101: Confirmed 2019-nCoV (novel coronavirus) infection
1240581000000104: 2019-nCoV (novel coronavirus) detected
1300721000000109: Coronavirus disease 19 caused by severe acute respiratory syndrome coronavirus 2 confirmed by laboratory test (situation)
1240751000000100: Disease caused by 2019-nCoV (novel coronavirus)
1240561000000108: Encephalopathy caused by 2019-nCoV (novel coronavirus)
1240571000000101: Gastroenteritis caused by 2019-nCoV (novel coronavirus)
1240531000000103: Myocarditis caused by 2019-nCoV (novel coronavirus)
1240521000000100: Otitis media caused by 2019-nCoV (novel coronavirus)
1240551000000105: Pneumonia caused by 2019-nCoV (novel coronavirus)
1240541000000107: Upper respiratory tract infection caused by 2019-nCoV (novel coronavirus)
1240511000000106: Detection of 2019-nCoV (novel coronavirus) using polymerase chain reaction technique
1240381000000105: Severe acute respiratory syndrome coronavirus 2 (organism)
1321541000000108: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) IgG detection result positive (added since 02/24/2021)
1321551000000106: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) IgM detection result positive (added since 02/24/2021)
1300731000000106: COVID-19 confirmed using clinical diagnostic criteria (added since 02/24/2021)
From 11/03/2020 and on: We added hospitalized COVID-19 GWAS and severe COVID-19 GWAS with primary care data (both TPP/CTV3 and EMIS/SNOMED CT) being released by UKBB. A hospitalized COVID-19 case is defined by a sample with inpatient diagnosis of COVID-19 (ICD 10 U071). A severe COVID-19 case is defined by a sample with COVID-19 death (ICD 10 U071) or with inpatient diagnosis of both COVID-19 and dependence on respirator (ICD 10 Z991 and Z9911) in the same instance index, or a COVID-10 case with advanced respiratory support (from inpatient critical care data). Due to limited case samples, currently we only conducted both hospitalized and sever COVID-19 GWAS for European and overall samples in UKBB – with 3 additional non-European GWAS for hospitalized COVID-19.
From 02/24/2021 and on: We added two COVID-19 GWAS in UKBB EAS samples, and three hospitalized COVID-19 GWAS for each of the UKBB AFR, SAS and OTHERS samples.
Note OTHERS samples include samples that are not EUR, AFR and SAS, thus EAS are included in OTHERS.
After each COVID-19 release of UK Biobank data (https://biobank.ctsu.ox.ac.uk/crystal/exinfo.cgi?src=timelines_all) we are calculating GWAS summary statistics and releasing them to this site. GWAS were conducted with SAIGE (https://github.com/weizhouUMICH/SAIGE) adjusted for baseline age, sex and 10 principal components.
- Two analyses (06/05/2020 or earlier):
- Positive COVID-19 tests vs. Negative only COVID-19 tests (files with name whites)
- Positive COVID-19 tests vs. All UKBioBank EA with either negative tests or no known tests (files with name “ALLwhites”)
- Eighteen analyses (06/18/2020):
- COVID-19 positive vs. COVID-19 negative in ALL UKBB tested samples (files with name UKBB_covid19_ALLtested)
- COVID-19 positive vs. COVID-19 negative or untested in ALL UKBB samples (files with name UKBB_covid19_ALL)
- COVID-19 positive vs. COVID-19 negative in European (EUR) UKBB tested samples (files with name UKBB_covid19_EURtested)
- COVID-19 positive vs. COVID-19 negative or untested in European (EUR) UKBB samples (files with name UKBB_covid19_EUR)
- COVID-19 positive vs. COVID-19 negative in ALL Female UKBB tested samples (files with name UKBB_covid19_ALLtested_F)
- COVID-19 positive vs. COVID-19 negative or untested in ALL Female UKBB samples (files with name UKBB_covid19_ALL_F)
- COVID-19 positive vs. COVID-19 negative in European (EUR) Female UKBB tested samples (files with name UKBB_covid19_EURtested_F)
- COVID-19 positive vs. COVID-19 negative or untested in European (EUR) Female UKBB samples (files with name UKBB_covid19_EUR_F)
- COVID-19 positive vs. COVID-19 negative in ALL Male UKBB tested samples (files with name UKBB_covid19_ALLtested_M)
- COVID-19 positive vs. COVID-19 negative or untested in ALL Male UKBB samples (files with name UKBB_covid19_ALL_M)
- COVID-19 positive vs. COVID-19 negative in European (EUR) Male UKBB tested samples (files with name UKBB_covid19_EURtested_M)
- COVID-19 positive vs. COVID-19 negative or untested in European (EUR) Male UKBB samples (files with name UKBB_covid19_EUR_M)
- COVID-19 positive vs. COVID-19 negative in African (AFR) UKBB tested samples (files with name UKBB_covid19_AFRtested)
- COVID-19 positive vs. COVID-19 negative or untested in African (AFR) UKBB samples (files with name UKBB_covid19_AFR)
- COVID-19 positive vs. COVID-19 negative in South Asian (SAS) UKBB tested samples (files with name UKBB_covid19_SAStested)
- COVID-19 positive vs. COVID-19 negative or untested in South Asian (SAS) UKBB samples (files with name UKBB_covid19_SAS)
- COVID-19 positive vs. COVID-19 negative in OTHERS ancestry UKBB tested samples (files with name UKBB_covid19_OTHERStested)
- COVID-19 positive vs. COVID-19 negative or untested in OTHERS ancestry UKBB samples (files with name UKBB_covid19_OTHERS)
- Six COVID-19 death analyses in addition to above 18 analyses (07/14/2020):
- COVID-19 death vs. COVID-19 negative or untested in ALL UKBB samples (files with name UKBB_death_ALL)
- COVID-19 death vs. COVID-19 negative or untested in European (EUR) UKBB samples (files with name UKBB_death_EUR)
- COVID-19 death vs. COVID-19 positive survivors in ALL UKBB tested positive samples (files with name UKBB_death_ALLpstv)
- COVID-19 death vs. COVID-19 positive survivors in European (EUR) UKBB tested positive samples (files with name UKBB_death_EURpstv)
- COVID-19 death vs. COVID-19 positive survivors and negative in ALL UKBB tested samples (files with name UKBB_death_ALLtested)
- COVID-19 death vs. COVID-19 positive survivors and negative in European (EUR) UKBB tested samples (files with name UKBB_death_EURtested)
- Two analyses in addition to the above 24 analyses (08/04/2020):
- COVID-19 positive vs. COVID-19 negative in non-European (nEUR) UKBB tested samples (files with name UKBB_covid19_nEURtested)
- COVID-19 positive vs. COVID-19 negative or untested in non-European (nEUR) UKBB samples (files with name UKBB_covid19_nEUR)
- Twenty-one hospitalized COVID-19 analyses (11/03/2020):
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in ALL UKBB tested positive samples (files with name UKBB_hsptl_ALLpstv)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in ALL UKBB tested samples (files with name UKBB_hsptl_ALLtested)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in ALL UKBB samples (files with name UKBB_hsptl_ALL)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in European (EUR) UKBB tested positive samples (files with name UKBB_hsptl_EURpstv)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in EUR UKBB tested samples (files with name UKBB_hsptl_EURtested)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in EUR UKBB samples (files with name UKBB_hsptl_EUR)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in non-European (nEUR) UKBB tested positive samples (files with name UKBB_hsptl_nEURpstv)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in nEUR UKBB tested samples (files with name UKBB_hsptl_nEURtested)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in nEUR UKBB samples (files with name UKBB_hsptl_nEUR)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in ALL Female UKBB tested positive samples (files with name UKBB_hsptl_ALLpstv_F)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in ALL Female UKBB tested samples (files with name UKBB_hsptl_ALLtested_F)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in ALL Female UKBB samples (files with name UKBB_hsptl_ALL_F)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in EUR Female UKBB tested positive samples (files with name UKBB_hsptl_EURpstv_F)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in EUR Female UKBB tested samples (files with name UKBB_hsptl_EURtested_F)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in EUR Female UKBB samples (files with name UKBB_hsptl_EUR_F)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in ALL Male UKBB tested positive samples (files with name UKBB_hsptl_ALLpstv_M)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in ALL Male UKBB tested samples (files with name UKBB_hsptl_ALLtested_M)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in ALL Male UKBB samples (files with name UKBB_hsptl_ALL_M)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in EUR Male UKBB tested positive samples (files with name UKBB_hsptl_EURpstv_M)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in EUR Male UKBB tested samples (files with name UKBB_hsptl_EURtested_M)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in EUR Male UKBB samples (files with name UKBB_hsptl_EUR_M)
- Eighteen severe COVID-19 analyses (11/03/2020):
- Severe COVID-19 positive vs. non-severe COVID-19 positive in ALL UKBB tested positive samples (files with name UKBB_severe_ALLpstv)
- Severe COVID-19 positive vs. non-severe COVID-19 positive or COVID-19 negative in ALL UKBB tested samples (files with name UKBB_severe_ALLtested)
- Severe COVID-19 positive vs. non-severe COVID-19 positive, COVID-19 negative or untested in ALL UKBB samples (files with name UKBB_severe_ALL)
- Severe COVID-19 positive vs. non-severe COVID-19 positive in European (EUR) UKBB tested positive samples (files with name UKBB_severe_EURpstv)
- Severe COVID-19 positive vs. non-severe COVID-19 positive or COVID-19 negative in EUR UKBB tested samples (files with name UKBB_severe_EURtested)
- Severe COVID-19 positive vs. non-severe COVID-19 positive, COVID-19 negative or untested in EUR UKBB samples (files with name UKBB_severe_EUR)
- Severe COVID-19 positive vs. non-severe COVID-19 positive in ALL Female UKBB tested positive samples (files with name UKBB_severe_ALLpstv_F)
- Severe COVID-19 positive vs. non-severe COVID-19 positive or COVID-19 negative in ALL Female UKBB tested samples (files with name UKBB_severe_ALLtested_F)
- Severe COVID-19 positive vs. non-severe COVID-19 positive, COVID-19 negative or untested in ALL Female UKBB samples (files with name UKBB_severe_ALL_F)
- Severe COVID-19 positive vs. non-severe COVID-19 positive in EUR Female UKBB tested positive samples (files with name UKBB_severe_EURpstv_F)
- Severe COVID-19 positive vs. non-severe COVID-19 positive or COVID-19 negative in EUR Female UKBB tested samples (files with name UKBB_severe_EURtested_F)
- Severe COVID-19 positive vs. non-severe COVID-19 positive, COVID-19 negative or untested in EUR Female UKBB samples (files with name UKBB_severe_EUR_F)
- Severe COVID-19 positive vs. non-severe COVID-19 positive in ALL Male UKBB tested positive samples (files with name UKBB_severe_ALLpstv_M)
- Severe COVID-19 positive vs. non-severe COVID-19 positive or COVID-19 negative in ALL Male UKBB tested samples (files with name UKBB_severe_ALLtested_M)
- Severe COVID-19 positive vs. non-severe COVID-19 positive, COVID-19 negative or untested in ALL Male UKBB samples (files with name UKBB_severe_ALL_M)
- Severe COVID-19 positive vs. non-severe COVID-19 positive in EUR Male UKBB tested positive samples (files with name UKBB_severe_EURpstv_M)
- Severe COVID-19 positive vs. non-severe COVID-19 positive or COVID-19 negative in EUR Male UKBB tested samples (files with name UKBB_severe_EURtested_M)
- Severe COVID-19 positive vs. non-severe COVID-19 positive, COVID-19 negative or untested in EUR Male UKBB samples (files with name UKBB_severe_EUR_M)
- Two additional COVID-19 analyses (02/24/2021):
- COVID-19 positive vs. COVID-19 negative in East Asian (EAS) UKBB tested samples (files with name UKBB_covid19_EAStested)
- COVID-19 positive vs. COVID-19 negative or untested in East Asian (EAS) UKBB samples (files with name UKBB_covid19_EAS)
- Nine additional hospitalized COVID-19 analyses (02/24/2021):
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in African (AFR) UKBB tested positive samples (files with name UKBB_hsptl_AFRpstv)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in AFR UKBB tested samples (files with name UKBB_hsptl_AFRtested)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in AFR UKBB samples (files with name UKBB_hsptl_AFR)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in South Asian (SAS) UKBB tested positive samples (files with name UKBB_hsptl_SASpstv)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in SAS UKBB tested samples (files with name UKBB_hsptl_SAStested)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in SAS UKBB samples (files with name UKBB_hsptl_SAS)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive in other ancestry (OTHERS) UKBB tested positive samples (files with name UKBB_hsptl_OTHERSpstv)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive or COVID-19 negative in OTHERS UKBB tested samples (files with name UKBB_hsptl_OTHERStested)
- Hospitalized COVID-19 positive vs. non-hospitalized COVID-19 positive, COVID-19 negative or untested in OTHERS UKBB samples (files with name UKBB_hsptl_OTHERS)
Summary statistics are for UK Biobank (v.3) imputed genome-wide association (GWAS) studies of COVID-19 test positives with variant filters of imputation quality INFO score >0.3, minor allele count (MAC) > 2, minor allele frequency > 0.0001. Note allele2 is coded allele. See SAIGE output description here: https://github.com/weizhouUMICH/SAIGE/wiki/Genetic-association-tests-using-SAIGE.
Ellinghaus, Degenhardt et al.
Meta-analysis of Spanish and Italian COVID19 cases with respiratory failure
NOTE: full GWAS files are GRCh38 build position whereas top results and annotated files have been Lifted Over to GRCh37.
COVID-19 Host Genetics initiative results provided under Creative Commons License. This includes meta-analyses of international case/control samples with a larger sample size than UKBB alone. These analyses may also have greater test/population ascertainment and genetic heterogeneity effects. If you have samples to contribute we urge you to consider joining. See also https://www.covid19hg.org/blog/ and https://www.nature.com/articles/s41431-020-0636-6
GenOMICC
GWAS of critically ill COVID patients. See also: https://genomicc.org/ and https://pubmed.ncbi.nlm.nih.gov/33307546/
Dube et al.
GWAS of time to remission of symptoms in the COVID colchicine trial COLCORONA. Before using data please see their terms and conditions here: https://pheweb.statgen.org/terms/pheweb/terms.html
Annotation of all top results P<1E-5 was done from several sources:
- Variant chromosomes, positions and alleles were mapped to SNP rsIDs with CellBase REST API (http://bioinfo.hpc.cam.ac.uk/cellbase/webservices/) described in https://pubmed.ncbi.nlm.nih.gov/22693220/
- The GRASP (full version with effect estimates) and GWAS catalog (5/17/20 version) was queried for intersecting variant associations by chromosome and position
- Variant annotations were queried against ANNOVAR and CADD (v.1.6).
Descriptions of annotation columns are found here - Expression QTLs were annotated with GTeX v.8 (https://www.gtexportal.org/home/) and with a literature based database of cis/trans eQTLs (many described in https://pubmed.ncbi.nlm.nih.gov/24973796/)
All files are in compressed Gzip format.
Send questions, comments or requests to add data or analysis to: ming-huei.chen@nih.gov, florian.thibord@nih.gov, and johnsonad2@nih.gov
| Data Source | Release Date | Description | # Cases / Controls | Ancestry | Sex | # variants (Million) | # Top (P<1E-5) | Summary Stats(full) | Top Annotated | Top in Grasp | Top in EBI | Top in GTeX | Top in eQTLdb | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UKBB | 06.18.21 | Positive vs. Population | 557 / 7,087 | African | M and F | 43.68M | 420 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 557 / 1,281 | African | M and F | 32.20M | 199 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 18,481 / 468,839 | Mixed | M and F | 47.70M | 972 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 9,757 / 254,472 | Mixed | F | 47.88M | 602 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 8,724 / 214,367 | Mixed | M | 47.45M | 556 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 18,481 / 86,435 | Mixed | M and F | 48.14M | 706 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 9,757 / 46,737 | Mixed | F | 48.35M | 485 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 8,724 / 39,698 | Mixed | M | 47.77M | 479 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 47 / 176 | East Asian | M and F | 305.99K | 71 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 16,551 / 442,699 | European | M and F | 38.06M | 856 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 8,767 / 240,532 | European | F | 38.11M | 412 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 7,784 / 202,167 | European | M | 37.98M | 419 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 16,551 / 81,826 | European | M and F | 38.08M | 466 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 8,767 / 44,248 | European | F | 38.09M | 314 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 7,784 / 37,578 | European | M | 37.98M | 399 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 1,930 / 26,140 | Non European | M and F | 66.62M | 747 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 1,930 / 4,609 | Non European | M and F | 52.38M | 545 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 563 / 10,446 | Other | M and F | 61.41M | 752 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 563 / 1,812 | Other | M and F | 35.05M | 296 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Population | 810 / 8,607 | South Asian | M and F | 41.98M | 325 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Positive vs. Negative (tested) | 810 / 1,516 | South Asian | M and F | 25.18M | 137 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 142 / 7,502 | African | M and F | 43.68M | 414 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 142 / 415 | African | M and F | 23.99M | 271 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 142 / 1,696 | African | M and F | 32.20M | 301 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 3,260 / 484,060 | Mixed | M and F | 47.70M | 722 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,343 / 262,886 | Mixed | F | 47.88M | 395 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,917 / 221,174 | Mixed | M | 47.45M | 531 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 3,260 / 15,221 | Mixed | M and F | 51.15M | 765 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,343 / 8,414 | Mixed | F | 45.13M | 486 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,917 / 6,807 | Mixed | M | 43.10M | 330 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 3,260 / 101,656 | Mixed | M and F | 48.14M | 698 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,343 / 55,151 | Mixed | F | 48.35M | 393 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,917 / 46,505 | Mixed | M | 47.77M | 676 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 2,884 / 456,366 | European | M and F | 38.06M | 757 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,181 / 248,118 | European | F | 38.11M | 325 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,703 / 208,248 | European | M | 37.98M | 370 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 2,884 / 13,667 | European | M and F | 37.83M | 584 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,181 / 7,586 | European | F | 32.32M | 309 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,703 / 6,081 | European | M | 30.99M | 333 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 2,884 / 95,493 | European | M and F | 38.08M | 665 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,181 / 51,834 | European | F | 38.09M | 287 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,703 / 43,659 | European | M | 37.98M | 624 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 376 / 27,694 | Non European | M and F | 66.62M | 597 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 376 / 1,554 | Non European | M and F | 34.25M | 335 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 376 / 6,163 | Non European | M and F | 52.38M | 442 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 103 / 10,906 | Other | M and F | 61.41M | 478 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 103 / 460 | Other | M and F | 21.46M | 165 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 103 / 2,272 | Other | M and F | 35.05M | 217 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 131 / 9,286 | South Asian | M and F | 41.98M | 235 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 131 / 679 | South Asian | M and F | 16.84M | 158 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 131 / 2,195 | South Asian | M and F | 25.18M | 163 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 532 / 7,112 | African | M and F | 42.11M | 354 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 532 / 995 | African | M and F | 29.67M | 191 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 17,657 / 469,663 | Mixed | M and F | 47.70M | 901 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 9,305 / 254,924 | Mixed | F | 47.88M | 579 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 8,352 / 214,739 | Mixed | M | 47.45M | 515 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 17,657 / 68,329 | Mixed | M and F | 48.18M | 734 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 9,305 / 36,945 | Mixed | F | 48.41M | 560 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 8,352 / 31,384 | Mixed | M | 47.76M | 509 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 47 / 1,456 | East Asian | M and F | 18.24M | 87 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 47 / 132 | East Asian | M and F | 9.02M | 33 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 15,815 / 443,435 | European | M and F | 38.06M | 814 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 8,363 / 240,936 | European | F | 38.11M | 442 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 7,452 / 202,499 | European | M | 37.98M | 490 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 15,815 / 64,744 | European | M and F | 38.02M | 468 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 8,363 / 34,997 | European | F | 38.01M | 325 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 7,452 / 29,747 | European | M | 37.91M | 409 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 535 / 10,474 | Other | M and F | 59.08M | 615 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 535 / 1,386 | Other | M and F | 31.11M | 282 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 775 / 8,642 | South Asian | M and F | 40.39M | 319 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 775 / 1,204 | South Asian | M and F | 22.73M | 133 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Population | 1,842 / 26,228 | Non European | M and F | 64.13M | 729 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive vs. Negative (tested) | 1,842 / 3,585 | Non European | M and F | 47.42M | 408 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive and Death vs. Population | 1,104 / 486,216 | Mixed | M and F | 47.70M | 489 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive and Death vs. Positive Survivor | 1,104 / 16,553 | Mixed | M and F | 51.10M | 494 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive and Death vs. Tested Survivor | 1,104 / 84,882 | Mixed | M and F | 48.18M | 564 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive and Death vs. Population | 1,001 / 458,249 | European | M and F | 38.06M | 344 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive and Death vs. Positive Survivor | 1,001 / 14,814 | European | M and F | 37.82M | 206 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Positive and Death vs. Tested Survivor | 1,001 / 79,558 | European | M and F | 38.02M | 276 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 139 / 7,505 | African | M and F | 43.68M | 384 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 139 / 393 | African | M and F | 23.71M | 277 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 139 / 1,388 | African | M and F | 30.79M | 292 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 3,109 / 484,211 | Mixed | M and F | 47.70M | 719 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,282 / 262,947 | Mixed | F | 47.88M | 450 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,827 / 221,264 | Mixed | M | 47.45M | 442 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 3,109 / 14,548 | Mixed | M and F | 51.10M | 643 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,282 / 8,023 | Mixed | F | 44.41M | 487 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,827 / 6,525 | Mixed | M | 42.49M | 360 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 3,109 / 82,877 | Mixed | M and F | 48.18M | 692 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,282 / 44,968 | Mixed | F | 48.41M | 424 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,827 / 37,909 | Mixed | M | 47.76M | 523 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 2,746 / 456,504 | European | M and F | 38.06M | 764 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,126 / 248,173 | European | F | 38.11M | 350 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,620 / 208,331 | European | M | 37.98M | 410 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 2,746 / 13,069 | European | M and F | 37.82M | 561 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,126 / 7,237 | European | F | 31.81M | 283 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,620 / 5,832 | European | M | 30.54M | 303 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 2,746 / 77,813 | European | M and F | 38.02M | 627 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,126 / 42,234 | European | F | 38.01M | 289 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,620 / 35,579 | European | M | 37.91M | 499 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 101 / 10,908 | Other | M and F | 61.41M | 481 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 101 / 434 | Other | M and F | 21.05M | 171 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 101 / 1,820 | Other | M and F | 32.32M | 189 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 123 / 9,294 | South Asian | M and F | 41.98M | 178 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 123 / 652 | South Asian | M and F | 16.59M | 141 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 123 / 1,856 | South Asian | M and F | 23.57M | 155 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 363 / 27,707 | Non European | M and F | 66.62M | 568 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 363 / 1,479 | Non European | M and F | 33.68M | 331 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 363 / 5,064 | Non European | M and F | 49.25M | 455 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 1,244 / 486,076 | Mixed | M and F | 47.70M | 739 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 439 / 263,790 | Mixed | F | 47.88M | 268 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 805 / 222,286 | Mixed | M | 47.45M | 457 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive | 1,244 / 16,413 | Mixed | M and F | 51.10M | 886 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive | 439 / 8,866 | Mixed | F | 44.41M | 320 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive | 805 / 7,547 | Mixed | M | 42.49M | 431 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative | 1,244 / 84,742 | Mixed | M and F | 48.18M | 1009 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative | 439 / 45,811 | Mixed | F | 48.41M | 257 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative | 805 / 38,931 | Mixed | M | 47.76M | 591 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 1,120 / 458,130 | European | M and F | 38.06M | 583 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 387 / 248,912 | European | F | 38.11M | 195 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 733 / 209,218 | European | M | 37.98M | 362 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive | 1,120 / 14,695 | European | M and F | 37.82M | 357 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive | 387 / 7,976 | European | F | 31.81M | 203 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive | 733 / 6,719 | European | M | 30.54M | 260 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative | 1,120 / 79,439 | European | M and F | 38.02M | 541 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative | 387 / 42,973 | European | F | 38.01M | 227 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.09.21 | Severe Positive vs. Non-Severe Positive or Negative | 733 / 36,466 | European | M | 37.91M | 346 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 519 / 7,125 | African | M and F | 43.68M | 376 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 519 / 889 | African | M and F | 30.18M | 237 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 16,586 / 470,734 | Mixed | M and F | 47.70M | 854 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 8,737 / 255,492 | Mixed | F | 47.88M | 584 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 7,849 / 215,242 | Mixed | M | 47.45M | 507 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 16,586 / 53,376 | Mixed | M and F | 48.81M | 679 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 8,737 / 28,511 | Mixed | F | 49.16M | 664 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 7,849 / 24,865 | Mixed | M | 48.22M | 450 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 43 / 1,460 | East Asian | M and F | 18.91M | 119 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 43 / 110 | East Asian | M and F | 9.07M | 102 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 14,810 / 444,440 | European | M and F | 38.06M | 795 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 7,823 / 241,476 | European | F | 38.11M | 416 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 6,987 / 202,964 | European | M | 37.98M | 545 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 14,810 / 50,320 | European | M and F | 38.11M | 424 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 7,823 / 26,824 | European | F | 38.12M | 392 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 6,987 / 23,496 | European | M | 37.98M | 388 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 1,776 / 26,294 | Non European | M and F | 66.62M | 696 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 1,776 / 3,056 | Non European | M and F | 47.34M | 396 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 516 / 10,493 | Other | M and F | 61.41M | 572 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 516 / 1,134 | Other | M and F | 30.64M | 291 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Population | 741 / 8,676 | South Asian | M and F | 41.98M | 332 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Positive vs. Negative (tested) | 741 / 1,033 | South Asian | M and F | 22.58M | 121 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,966 / 485,354 | Mixed | M and F | 47.70M | 515 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 760 / 263,469 | Mixed | F | 47.88M | 386 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,206 / 221,885 | Mixed | M | 47.45M | 500 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,966 / 14,620 | Mixed | M and F | 51.30M | 520 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 760 / 7,977 | Mixed | F | 43.73M | 353 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,206 / 6,643 | Mixed | M | 41.76M | 600 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,966 / 67,996 | Mixed | M and F | 48.81M | 528 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 760 / 36,488 | Mixed | F | 49.16M | 409 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,206 / 31,508 | Mixed | M | 48.22M | 629 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,755 / 457,495 | European | M and F | 38.06M | 485 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 676 / 248,623 | European | F | 38.11M | 383 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,079 / 208,872 | European | M | 37.98M | 492 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,755 / 13,055 | European | M and F | 37.86M | 426 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 676 / 7,147 | European | F | 31.18M | 282 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,079 / 5,908 | European | M | 29.91M | 391 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,755 / 63,375 | European | M and F | 38.11M | 457 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 676 / 33,971 | European | F | 38.12M | 426 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 04.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,079 / 29,404 | European | M | 37.98M | 500 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 496 / 7,148 | African | M and F | 43.68M | 399 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 496 / 809 | African | M and F | 29.60M | 198 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 15,738 / 471,582 | Mixed | M and F | 47.70M | 896 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 8,258 / 255,971 | Mixed | F | 47.88M | 664 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 7,480 / 215,611 | Mixed | M | 47.45M | 495 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 15,738 / 47,413 | Mixed | M and F | 48.93M | 697 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 8,258 / 25,373 | Mixed | F | 49.27M | 620 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 7,480 / 22,040 | Mixed | M | 48.35M | 460 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 41 / 1,462 | East Asian | M and F | 18.91M | 125 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 41 / 94 | East Asian | M and F | 8.84M | 72 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 14,054 / 445,196 | European | M and F | 38.06M | 789 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 7,396 / 241,903 | European | F | 38.11M | 429 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 6,658 / 203,293 | European | M | 37.98M | 433 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 14,054 / 44,646 | European | M and F | 38.10M | 438 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 7,396 / 23,847 | European | F | 38.08M | 504 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 6,658 / 20,799 | European | M | 37.94M | 323 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 1,684 / 26,386 | Non European | M and F | 66.62M | 811 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 1,684 / 2,767 | Non European | M and F | 46.01M | 322 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 495 / 10,514 | Other | M and F | 61.41M | 529 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 495 / 1,020 | Other | M and F | 29.72M | 397 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Population | 693 / 8,724 | South Asian | M and F | 41.98M | 387 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive vs. Negative (tested) | 693 / 938 | South Asian | M and F | 21.84M | 110 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive and Death vs. Population | 828 / 486,492 | Mixed | M and F | 47.70M | 438 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive and Death vs. Positive Survivor | 828 / 14,910 | Mixed | M and F | 51.30M | 629 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive and Death vs. Tested Survivor | 828 / 62,323 | Mixed | M and F | 48.93M | 434 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive and Death vs. Population | 758 / 458,492 | European | M and F | 38.06M | 371 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive and Death vs. Positive Survivor | 758 / 13,296 | European | M and F | 37.33M | 243 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Positive and Death vs. Tested Survivor | 758 / 57,942 | European | M and F | 38.10M | 340 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 77 / 7,567 | African | M and F | 43.68M | 317 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 77 / 419 | African | M and F | 23.28M | 257 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 77 / 1,228 | African | M and F | 29.60M | 262 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,916 / 485,404 | Mixed | M and F | 47.70M | 473 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 735 / 263,494 | Mixed | F | 47.88M | 323 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,181 / 221,910 | Mixed | M | 47.45M | 521 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,916 / 13,822 | Mixed | M and F | 51.30M | 612 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 735 / 7,523 | Mixed | F | 42.94M | 349 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,181 / 6,299 | Mixed | M | 41.07M | 526 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,916 / 61,235 | Mixed | M and F | 48.93M | 525 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 735 / 32,896 | Mixed | F | 49.27M | 341 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,181 / 28,339 | Mixed | M | 48.35M | 611 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,712 / 457,538 | European | M and F | 38.06M | 468 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 655 / 248,644 | European | F | 38.11M | 297 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,057 / 208,894 | European | M | 37.98M | 483 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,712 / 12,342 | European | M and F | 37.33M | 515 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 655 / 6,741 | European | F | 30.62M | 310 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,057 / 5,601 | European | M | 29.42M | 266 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,712 / 56,988 | European | M and F | 38.10M | 518 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 655 / 30,588 | European | F | 38.08M | 375 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,057 / 26,400 | European | M | 37.94M | 412 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 204 / 27,866 | Non European | M and F | 66.62M | 620 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 204 / 1,480 | Non European | M and F | 32.66M | 247 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 204 / 4,247 | Non European | M and F | 46.01M | 331 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 62 / 10,947 | Other | M and F | 61.41M | 475 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 62 / 433 | Other | M and F | 20.49M | 258 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 62 / 1,453 | Other | M and F | 29.72M | 230 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 65 / 9,352 | South Asian | M and F | 41.98M | 190 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 65 / 628 | South Asian | M and F | 15.97M | 109 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 65 / 1,566 | South Asian | M and F | 21.84M | 67 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 935 / 486,385 | Mixed | M and F | 47.70M | 487 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 320 / 263,909 | Mixed | F | 47.88M | 390 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 615 / 222,476 | Mixed | M | 47.45M | 345 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive | 935 / 14,803 | Mixed | M and F | 51.30M | 713 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive | 320 / 7,938 | Mixed | F | 42.94M | 445 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive | 615 / 6,865 | Mixed | M | 41.07M | 432 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative | 935 / 62,216 | Mixed | M and F | 48.93M | 585 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative | 320 / 33,311 | Mixed | F | 49.27M | 368 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative | 615 / 28,905 | Mixed | M | 48.35M | 502 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 848 / 458,402 | European | M and F | 38.06M | 440 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 283 / 249,016 | European | F | 38.11M | 280 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 565 / 209,386 | European | M | 37.98M | 341 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive | 848 / 13,206 | European | M and F | 37.33M | 292 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive | 283 / 7,113 | European | F | 30.62M | 185 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive | 565 / 6,093 | European | M | 29.42M | 308 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative | 848 / 57,852 | European | M and F | 38.10M | 462 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative | 283 / 30,960 | European | F | 38.08M | 228 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.24.21 | Severe Positive vs. Non-Severe Positive or Negative | 565 / 26,892 | European | M | 37.94M | 405 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 13,232 / 41,374 | European | M and F | 38.10M | 526 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 13,232 / 446,018 | European | M and F | 38.06M | 804 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 14,802 / 43,990 | Mixed | M and F | 48.99M | 673 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 14,802 / 472,518 | Mixed | M and F | 47.70M | 825 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 470 / 769 | African | M and F | 29.23M | 181 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 470 / 7,174 | African | M and F | 43.68M | 313 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 638 / 905 | South Asian | M and F | 21.37M | 163 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 638 / 8,779 | South Asian | M and F | 41.98M | 395 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 462 / 942 | Other | M and F | 28.87M | 419 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 462 / 10,547 | Other | M and F | 61.41M | 540 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 1,570 / 2,616 | Non European | M and F | 45.03M | 343 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 1,570 / 26,500 | Non European | M and F | 66.62M | 748 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 6,950 / 22,105 | European | F | 38.07M | 427 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 6,950 / 242,349 | European | F | 38.11M | 461 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 7,762 / 23,548 | Mixed | F | 49.36M | 592 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 7,762 / 256,467 | Mixed | F | 47.88M | 575 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 6,282 / 19,269 | European | M | 37.95M | 363 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 6,282 / 203,669 | European | M | 37.98M | 433 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Negative (tested) | 7,040 / 20,442 | Mixed | M | 48.32M | 503 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 02.02.21 | Positive vs. Population | 7,040 / 216,051 | Mixed | M | 47.45M | 508 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 12,014 / 39,737 | European | M and F | 38.10M | 518 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 12,014 / 447,236 | European | M and F | 38.06M | 770 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 13,401 / 42,261 | Mixed | M and F | 48.87M | 679 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 13,401 / 473,919 | Mixed | M and F | 47.70M | 795 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 395 / 730 | African | M and F | 28.53M | 227 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 395 / 7,249 | African | M and F | 43.68M | 318 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 576 / 879 | South Asian | M and F | 20.89M | 95 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 576 / 8,841 | South Asian | M and F | 41.98M | 361 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 416 / 915 | Other | M and F | 28.31M | 269 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 416 / 10,593 | Other | M and F | 61.41M | 486 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 1,387 / 2,524 | Non European | M and F | 43.94M | 322 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 1,387 / 26,683 | Non European | M and F | 66.62M | 642 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 6,298 / 21,239 | European | F | 38.06M | 426 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 6,298 / 243,001 | European | F | 38.11M | 411 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 7,005 / 22,634 | Mixed | F | 49.24M | 579 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 7,005 / 257,224 | Mixed | F | 47.88M | 528 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 5,716 / 18,498 | European | M | 37.97M | 365 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 5,716 / 204,235 | European | M | 37.98M | 506 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Negative (tested) | 6,396 / 19,627 | Mixed | M | 47.82M | 446 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive vs. Population | 6,396 / 216,695 | Mixed | M | 48.18M | 530 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive and Death vs. Population | 646 / 486,674 | Mixed | M and F | 47.70M | 386 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive and Death vs. Population | 589 / 458,661 | European | M and F | 38.06M | 336 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive and Death vs. Positive Survivor | 646 / 12,755 | Mixed | M and F | 49.40M | 540 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive and Death vs. Positive Survivor | 589 / 11,425 | European | M and F | 35.63M | 269 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive and Death vs. Tested Survivor | 646 / 55,016 | Mixed | M and F | 48.87M | 476 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Positive and Death vs. Tested Survivor | 589 / 51,162 | European | M and F | 38.10M | 334 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,403 / 457,847 | European | M and F | 38.06M | 740 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,403 / 10,611 | European | M and F | 35.63M | 498 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,403 / 50,348 | European | M and F | 38.10M | 611 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 1,573 / 485,747 | Mixed | M and F | 47.70M | 552 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 1,573 / 11,828 | Mixed | M and F | 49.40M | 567 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 1,573 / 54,089 | Mixed | M and F | 47.82M | 559 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 170 / 27,900 | Non European | M and F | 66.62M | 552 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 170 / 1,217 | Non European | M and F | 30.47M | 180 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 170 / 3,741 | Non European | M and F | 43.94M | 319 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 529 / 248,770 | European | F | 38.11M | 323 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 529 / 5,769 | European | F | 28.97M | 241 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 529 / 27,008 | European | F | 38.06M | 359 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 600 / 263,629 | Mixed | F | 47.88M | 371 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 600 / 6,405 | Mixed | F | 40.39M | 339 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 600 / 29,039 | Mixed | F | 49.02M | 377 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 874 / 209,077 | European | M | 37.98M | 726 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 874 / 4,842 | European | M | 27.83M | 240 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 874 / 23,340 | European | M | 37.97M | 527 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 973 / 222,118 | Mixed | M | 47.45M | 745 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 973 / 5,423 | Mixed | M | 38.54M | 422 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 973 / 25,050 | Mixed | M | 48.18M | 677 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 666 / 458,584 | European | M and F | 38.06M | 364 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive | 666 / 11,348 | European | M and F | 35.63M | 311 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative | 666 / 51,085 | European | M and F | 38.10M | 373 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 737 / 486,583 | Mixed | M and F | 47.70M | 399 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive | 737 / 12,664 | Mixed | M and F | 49.40M | 567 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative | 737 / 54,925 | Mixed | M and F | 48.87M | 458 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 215 / 249,084 | European | F | 38.11M | 311 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive | 215 / 6,083 | European | F | 28.97M | 164 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative | 215 / 27,322 | European | F | 38.06M | 240 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 247 / 263,982 | Mixed | F | 47.88M | 400 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive | 247 / 6,758 | Mixed | F | 40.39M | 420 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative | 247 / 29,392 | Mixed | F | 49.24M | 427 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 451 / 209,500 | European | M | 37.98M | 353 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive | 451 / 5,265 | European | M | 27.83M | 284 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative | 451 / 23,763 | European | M | 37.97M | 481 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 490 / 222,601 | Mixed | M | 47.45M | 343 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive | 490 / 5,906 | Mixed | M | 38.54M | 346 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.22.21 | Severe Positive vs. Non-Severe Positive or Negative | 490 / 25,533 | Mixed | M | 48.18M | 507 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 7,935 / 35,579 | European | M and F | 38.09M | 496 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 7,935 / 451,315 | European | M and F | 38.06M | 581 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 8,722 / 37,939 | Mixed | M and F | 48.59M | 624 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 8,722 / 478,598 | Mixed | M and F | 47.70M | 652 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 213 / 678 | African | M and F | 26.91M | 344 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 213 / 7,431 | African | M and F | 43.68M | 383 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 351 / 836 | South Asian | M and F | 19.32M | 169 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 351 / 9,066 | South Asian | M and F | 41.98M | 335 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 223 / 846 | Other | M and F | 26.21M | 521 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 223 / 10,786 | Other | M and F | 61.41M | 463 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 787 / 2,360 | Non European | M and F | 40.68M | 334 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 787 / 27,283 | Non European | M and F | 66.62M | 587 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 4,020 / 18,917 | European | F | 38.03M | 558 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 4,020 / 245,279 | European | F | 38.11M | 451 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 4,405 / 20,226 | Mixed | F | 49.02M | 477 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 4,405 / 259,824 | Mixed | F | 47.88M | 395 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 3,915 / 16,662 | European | M | 37.93M | 685 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 3,915 / 206,036 | European | M | 37.98M | 508 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Negative (tested) | 4,317 / 17,713 | Mixed | M | 47.82M | 502 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive vs. Population | 4,317 / 218,774 | Mixed | M | 47.45M | 504 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive and Death vs. Population | 474 / 486,846 | Mixed | M and F | 47.70M | 590 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive and Death vs. Population | 427 / 458,823 | European | M and F | 38.06M | 501 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive and Death vs. Positive Survivor | 474 / 8,248 | Mixed | M and F | 42.31M | 568 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive and Death vs. Positive Survivor | 427 / 7,508 | European | M and F | 31.14M | 435 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive and Death vs. Tested Survivor | 474 / 46,187 | Mixed | M and F | 48.59M | 615 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Positive and Death vs. Tested Survivor | 427 / 43,087 | European | M and F | 38.09M | 485 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 802 / 458,448 | European | M and F | 38.06M | 565 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 802 / 7,133 | European | M and F | 31.14M | 366 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 802 / 42,712 | European | M and F | 38.09M | 542 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 932 / 486,388 | Mixed | M and F | 47.70M | 447 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 932 / 7,790 | Mixed | M and F | 42.31M | 441 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 932 / 45,729 | Mixed | M and F | 47.82M | 502 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 130 / 27,940 | Non European | M and F | 66.62M | 564 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 130 / 657 | Non European | M and F | 25.17M | 125 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 130 / 3,017 | Non European | M and F | 40.68M | 274 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 299 / 249,000 | European | F | 38.11M | 292 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 299 / 3,721 | European | F | 24.60M | 157 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 299 / 22,638 | European | F | 38.03M | 294 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 357 / 263,872 | Mixed | F | 47.88M | 366 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 357 / 4,048 | Mixed | F | 33.42M | 289 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 357 / 24,274 | Mixed | F | 49.02M | 405 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 503 / 209,448 | European | M | 37.98M | 525 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 503 / 3,412 | European | M | 24.26M | 231 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 503 / 20,074 | European | M | 37.93M | 400 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 575 / 222,516 | Mixed | M | 47.45M | 756 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive | 575 / 3,742 | Mixed | M | 32.73M | 291 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 575 / 21,455 | Mixed | M | 47.82M | 676 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 482 / 458,768 | European | M and F | 38.06M | 518 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive | 482 / 7,453 | European | M and F | 31.14M | 408 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative | 482 / 43,032 | European | M and F | 38.09M | 420 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 541 / 486,779 | Mixed | M and F | 47.70M | 522 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive | 541 / 8,181 | Mixed | M and F | 42.31M | 592 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative | 541 / 46,120 | Mixed | M and F | 48.59M | 557 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 156 / 249,143 | European | F | 38.11M | 319 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive | 156 / 3,864 | European | F | 24.60M | 154 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative | 156 / 22,781 | European | F | 38.03M | 207 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 184 / 264,045 | Mixed | F | 47.88M | 334 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive | 184 / 4,221 | Mixed | F | 33.42M | 317 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative | 184 / 24,447 | Mixed | F | 49.02M | 444 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 326 / 209,625 | European | M | 37.98M | 419 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive | 326 / 3,589 | European | M | 24.26M | 158 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative | 326 / 20,251 | European | M | 37.93M | 319 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 357 / 222,734 | Mixed | M | 47.45M | 297 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive | 357 / 3,960 | Mixed | M | 32.73M | 254 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 01.04.21 | Severe Positive vs. Non-Severe Positive or Negative | 357 / 21,673 | Mixed | M | 47.82M | 369 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 6,803 / 32,205 | European | M and F | 38.07M | 460 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 6,803 / 452,447 | European | M and F | 38.06M | 593 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 7,435 / 34,362 | Mixed | M and F | 48.51M | 584 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 7,435 / 479,885 | Mixed | M and F | 47.70M | 688 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 174 / 610 | African | M and F | 26.07M | 190 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 174 / 7,470 | African | M and F | 43.68M | 520 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 282 / 773 | South Asian | M and F | 18.50M | 245 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 282 / 9,135 | South Asian | M and F | 41.98M | 366 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 176 / 774 | Other | M and F | 25.23M | 368 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 176 / 10,833 | Other | M and F | 61.41M | 500 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 632 / 2,157 | Non European | M and F | 38.96M | 413 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 632 / 27,438 | Non European | M and F | 66.62M | 635 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 3,438 / 17,065 | European | F | 37.99M | 381 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 3,438 / 245,861 | European | F | 38.11M | 393 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 3,752 / 18,252 | Mixed | F | 48.95M | 616 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 3,752 / 260,477 | Mixed | F | 47.88M | 552 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 3,365 / 15,140 | European | M | 37.92M | 876 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 3,365 / 206,586 | European | M | 37.98M | 449 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Negative (tested) | 3,683 / 16,110 | Mixed | M | 47.72M | 476 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 12.04.20 | Positive vs. Population | 3,683 / 219,408 | Mixed | M | 47.45M | 458 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 5,356 / 28,118 | European | M and F | 38.05M | 472 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 5,356 / 453,894 | European | M and F | 38.06M | 557 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 5,868 / 30,028 | Mixed | M and F | 48.59M | 604 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 5,868 / 481,452 | Mixed | M and F | 47.70M | 644 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 147 / 542 | African | M and F | 25.24M | 169 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 147 / 7,497 | African | M and F | 43.68M | 351 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 232 / 685 | South Asian | M and F | 17.60M | 266 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 232 / 9,185 | South Asian | M and F | 41.98M | 315 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 133 / 683 | Other | M and F | 23.97M | 328 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 133 / 10,876 | Other | M and F | 61.41M | 364 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 512 / 1,910 | Non European | M and F | 37.06M | 387 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 512 / 27,558 | Non European | M and F | 66.62M | 688 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 2,656 / 14,838 | European | F | 37.95M | 455 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 2,656 / 246,643 | European | F | 38.11M | 470 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 2,906 / 15,886 | Mixed | F | 49.09M | 589 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 2,906 / 261,323 | Mixed | F | 47.88M | 508 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 2,700 / 13,280 | European | M | 37.85M | 571 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 2,700 / 207,251 | European | M | 37.98M | 440 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Negative (tested) | 2,962 / 14,142 | Mixed | M | 47.67M | 452 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.25.20 | Positive vs. Population | 2,962 / 220,129 | Mixed | M | 47.45M | 428 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 3,962 / 25,845 | European | M and F | 38.06M | 427 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 3,962 / 455,288 | European | M and F | 38.06M | 500 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 4,372 / 27,629 | Mixed | M and F | 48.73M | 511 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 4,372 / 482,948 | Mixed | M and F | 47.70M | 648 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 130 / 508 | African | M and F | 24.76M | 154 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 130 / 7,514 | African | M and F | 43.68M | 352 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 180 / 645 | South Asian | M and F | 16.96M | 181 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 180 / 9,237 | South Asian | M and F | 41.98M | 290 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 100 / 631 | Other | M and F | 23.15M | 276 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 100 / 10,909 | Other | M and F | 61.41M | 420 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 410 / 1,784 | Non European | M and F | 35.82M | 374 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 410 / 27,660 | Non European | M and F | 66.62M | 477 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 1,953 / 13,591 | European | F | 37.95M | 348 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 1,953 / 247,346 | European | F | 38.11M | 363 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 2,159 / 14,564 | Mixed | F | 42.21M | 504 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 2,159 / 262,070 | Mixed | F | 47.88M | 395 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 2,009 / 12,254 | European | M | 37.43M | 397 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 2,009 / 207,942 | European | M | 37.98M | 491 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Negative (tested) | 2,213 / 13,065 | Mixed | M | 47.81M | 442 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive vs. Population | 2,213 / 220,878 | Mixed | M | 47.45M | 521 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive and Death vs. Population | 418 / 486,902 | Mixed | M and F | 47.70M | 450 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive and Death vs. Population | 377 / 458,873 | European | M and F | 38.06M | 348 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive and Death vs. Positive Survivor | 418 / 3,954 | Mixed | M and F | 33.64M | 298 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive and Death vs. Positive Survivor | 377 / 3,585 | European | M and F | 24.36M | 202 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive and Death vs. Tested Survivor | 418 / 31,583 | Mixed | M and F | 48.73M | 573 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Positive and Death vs. Tested Survivor | 377 / 29,430 | European | M and F | 38.07M | 363 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 678 / 458,572 | European | M and F | 38.06M | 575 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive | 678 / 3,284 | European | M and F | 24.36M | 271 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 678 / 29,129 | European | M and F | 38.07M | 524 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 794 / 486,526 | Mixed | M and F | 47.70M | 522 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive | 794 / 3,578 | Mixed | M and F | 33.64M | 376 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 794 / 31,207 | Mixed | M and F | 48.73MM | 573 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 116 / 27,954 | Non European | M and F | 66.62M | 434 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive | 116 / 294 | Non European | M and F | 20.80M | 140 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 116 / 2,078 | Non European | M and F | 35.82M | 227 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 246 / 249,053 | European | F | 38.11M | 311 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive | 246 / 1,707 | European | F | 19.11M | 145 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 246 / 15,298 | European | F | 37.95M | 281 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 297 / 263,932 | Mixed | F | 47.88M | 378 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive | 297 / 1,862 | Mixed | F | 26.19M | 151 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 297 / 16,426 | Mixed | F | 49.21M | 454 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 432 / 209,519 | European | M | 37.98M | 372 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive | 432 / 1,577 | European | M | 19.24M | 187 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 432 / 13,831 | European | M | 37.43M | 424 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative or Untested | 497 / 222,594 | Mixed | M | 47.45M | 484 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive | 497 / 1,716 | Mixed | M | 25.51M | 215 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Hospitalized Positive vs. Non-Hospitalized Positive or Negative | 497 / 14,781 | Mixed | M | 47.81M | 532 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 421 / 458,829 | European | M and F | 38.06M | 384 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive | 421 / 3,541 | European | M and F | 24.36M | 200 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative | 421 / 29,386 | European | M and F | 38.07M | 273 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 474 / 486,846 | Mixed | M and F | 47.70M | 378 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive | 474 / 3,898 | Mixed | M and F | 33.64M | 348 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative | 474 / 31,527 | Mixed | M and F | 48.73M | 436 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 146 / 249,153 | European | F | 38.11M | 276 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive | 146 / 1,807 | European | F | 19.11M | 233 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative | 146 / 15,398 | European | F | 37.95M | 269 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 171 / 264,058 | Mixed | F | 47.88M | 441 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive | 171 / 1,988 | Mixed | F | 26.19M | 235 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative | 171 / 16,552 | Mixed | F | 49.21M | 488 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 275 / 209,676 | European | M | 37.98M | 329 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive | 275 / 1,734 | European | M | 19.24M | 168 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative | 275 / 13,988 | European | M | 37.43M | 284 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative or Untested | 303 / 222,788 | Mixed | M | 47.45M | 296 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive | 303 / 1,910 | Mixed | M | 25.51M | 177 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 11.03.20 | Severe Positive vs. Non-Severe Positive or Negative | 303 / 14,975 | Mixed | M | 47.81M | 325 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 2,727 / 23,249 | European | M and F | 38.03M | 323 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 2,727 / 456,523 | European | M and F | 38.06M | 389 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 3,050 / 24,853 | Mixed | M and F | 48.79M | 426 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 3,050 / 484,270 | Mixed | M and F | 47.70M | 451 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 114 / 452 | African | M and F | 24.05M | 171 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 114 / 7,530 | African | M and F | 43.68M | 272 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 133 / 587 | South Asian | M and F | 16.21M | 173 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 133 / 9,284 | South Asian | M and F | 41.98M | 485 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 76 / 565 | Other | M and F | 22.15M | 179 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 76 / 10,933 | Other | M and F | 61.41M | 260 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 323 / 1,604 | Non European | M and F | 34.25M | 278 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 323 / 27,747 | Non European | M and F | 66.62M | 223 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 1,325 / 12,172 | European | F | 36.92M | 354 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 1,325 / 247,974 | European | F | 38.11M | 523 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 1,485 / 13,040 | Mixed | F | 48.88M | 422 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 1,485 / 262,744 | Mixed | F | 47.88M | 484 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 1,402 / 11,077 | European | M | 36.05M | 349 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 1,402 / 208,549 | European | M | 37.98M | 332 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Negative (tested) | 1,565 / 11,813 | Mixed | M | 46.48M | 406 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 10.16.20 | Positive vs. Population | 1,565 / 221,526 | Mixed | M | 47.45M | 432 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive and Death vs. Population | 416 / 486,904 | Mixed | M and F | 47.70M | 450 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive and Death vs. Population | 375 / 458,875 | European | M and F | 38.06M | 365 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive and Death vs. Positive Survivor | 416 / 1,405 | Mixed | M and F | 25.98M | 159 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive and Death vs. Positive Survivor | 375 / 1,207 | European | M and F | 17.85M | 117 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive and Death vs. Tested Survivor | 416 / 17,302 | Mixed | M and F | 49.04M | 722 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive and Death vs. Tested Survivor | 375 / 16,068 | European | M and F | 37.96M | 442 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 1,582 / 14,861 | European | M and F | 37.96M | 333 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 1,582 / 457,668 | European | M and F | 38.06M | 419 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 1,821 / 15,897 | Mixed | M and F | 49.04M | 374 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 1,821 / 485,499 | Mixed | M and F | 47.70M | 437 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 96 / 288 | African | M and F | 21.83M | 102 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 96 / 7,548 | African | M and F | 43.68M | 311 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 80 / 362 | South Asian | M and F | 13.89M | 135 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 80 / 9,337 | South Asian | M and F | 41.98M | 548 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 63 / 386 | Other | M and F | 19.92M | 70 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 63 / 10,946 | Other | M and F | 61.41M | 189 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 239 / 1,036 | Non European | M and F | 29.78M | 250 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 239 / 27,831 | Non European | M and F | 66.62M | 238 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 736 / 7,709 | European | F | 32.00M | 311 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 736 / 248,563 | European | F | 38.11M | 482 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 851 / 8,271 | Mixed | F | 42.92M | 420 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 851 / 263,378 | Mixed | F | 47.88M | 300 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 846 / 7,152 | European | M | 31.40M | 311 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 846 / 209,105 | European | M | 37.98M | 459 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Negative (tested) | 970 / 7,626 | Mixed | M | 40.61M | 339 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 09.08.20 | Positive vs. Population | 970 / 222,121 | Mixed | M | 47.45M | 708 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 1,503 / 10,632 | European | M and F | 35.77M | 344 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 1,503 / 457,747 | European | M and F | 38.06M | 408 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 1,723 / 11,409 | Mixed | M and F | 47.68M | 340 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 1723 / 485,597 | Mixed | M and F | 47.70M | 411 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 88 / 229 | African | M and F | 20.84M | 98 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 88 / 7,556 | African | M and F | No change since 07.14.20 analysis | ||||||||
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 73 / 254 | South Asian | M and F | 12.77M | 137 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 73 / 9,344 | South Asian | M and F | 41.98M | 636 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 59 / 294 | Other | M and F | 18.49M | 71 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 59 / 10,950 | Other | M and F | 61.41M | 121 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 220 / 777 | Non European | M and F | 27.56M | 209 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 220 / 27,850 | Non European | M and F | 66.62M | 315 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 699 / 5,452 | European | F | 28.66M | 205 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 699 / 248,600 | European | F | 38.11M | 352 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 804 / 5,887 | Mixed | F | 39.16M | 285 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 804 / 263,425 | Mixed | F | 47.88M | 315 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 804 / 5,180 | European | M | 28.35M | 300 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 804 / 209,147 | European | M | 37.98M | 450 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Negative (tested) | 919 / 5,522 | Mixed | M | 37.00M | 519 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 08.04.20 | Positive vs. Population | 919 / 222,172 | Mixed | M | 47.45M | 590 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive and Death vs. Population | 364 / 486,956 | Mixed | M and F | 47.70M | 437 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive and Death vs. Population | 325 / 458,925 | European | M and F | 38.06M | 365 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive and Death vs. Positive Survivor | 364 / 1,306 | Mixed | M and F | 25.16M | 127 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive and Death vs. Positive Survivor | 325 / 1,129 | European | M and F | 17.38M | 130 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive and Death vs. Tested Survivor | 364 / 8,874 | Mixed | M and F | 47.70M | 403 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive and Death vs. Tested Survivor | 325 / 8,161 | European | M and F | 31.99M | 288 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 1,454 / 7,032 | European | M and F | 31.99M | 293 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 1,454 / 457,796 | European | M and F | 38.06M | 385 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 1,670 / 7,568 | Mixed | M and F | 43.28M | 304 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 1,670 / 485,650 | Mixed | M and F | 47.70M | 426 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 88 / 167 | African | M and F | 19.75M | 70 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 88 / 7,556 | African | M and F | 43.68M | 334 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 70 / 167 | South Asian | M and F | 11.77M | 69 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 70 / 9,347 | South Asian | M and F | 41.98M | 761 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 58 / 202 | Other | M and F | 16.94M | 46 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 58 / 10,951 | Other | M and F | 61.41M | 228 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 674 / 3,611 | European | F | 25.20M | 260 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 674 / 248,625 | European | F | 38.11M | 345 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 778 / 3,917 | Mixed | F | 35.00M | 371 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 778 / 263,451 | Mixed | F | 47.88M | 404 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 780 / 3,421 | European | M | 25.03 | 244 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 780 / 209,171 | European | M | 37.98M | 393 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Negative (tested) | 892 / 3,651 | Mixed | M | 32.98M | 418 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 07.14.20 | Positive vs. Population | 892 / 222,199 | Mixed | M | 47.45M | 597 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 1,291 / 5,455 | European | M and F | 29.61M | 304 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 1,291 / 457,959 | European | M and F | 38.06M | 379 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 1,485 / 5,877 | Mixed | M and F | 40.32M | 269 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 1,485 / 485,835 | Mixed | M and F | 47.70M | 395 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 77 / 135 | African | M and F | 18.87M | 93 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 77 / 7,567 | African | M and F | 43.68M | 293 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 64 / 135 | South Asian | M and F | 11.29M | 47 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 64 / 9,353 | South Asian | M and F | 41.98M | 722 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 53 / 152 | Other | M and F | 15.58M | 89 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 53 / 10,956 | Other | M and F | 61.41M | 200 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 610 / 2,779 | European | F | 22.13M | 228 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 610 / 248,689 | European | F | 38.11M | 447 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 701 / 3,014 | Mixed | F | 32.30M | 308 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 701 / 263,528 | Mixed | F | 47.88M | 265 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 681 / 2,676 | European | M | 23.09M | 338 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 681 / 209,270 | European | M | 37.98M | 337 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Negative (tested) | 784 / 2,863 | Mixed | M | 30.60M | 313 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.18.20 | Positive vs. Population | 784 / 222,307 | Mixed | M | 47.45M | 419 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 06.05.20 | Positive vs. Negative (tested) | 1,221 / 4,117 | European | M and F | 27.26 M | 244 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQTLdb | |
| UKBB | 06.05.20 | Positive vs. Population | 1,221 / 458,029 | European | M and F | 38.06 M | 406 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQTLdb | |
| UKBB | 05.25.20 | Positive vs. Negative (tested) | 1,095/ 2,797 | European | M and F | 24.33 M | 172 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.25.20 | Positive vs. Population | 1,095 / 458,155 | European | M and F | 38.06 M | 448 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.07.20 | Positive vs. Negative (tested) | 880 / 1,686 | European | M and F | 21.03 M | 205 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| UKBB | 05.07.20 | Positive vs. Population | 880 / 458,370 | European | M and F | 38.06 M | 374 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 06.07.21 | Very severe respiratory confirmed covid vs. population (A2) | 8,779 / 1,001,875 | Mixed | M and F | 8.14M | 3800 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 06.07.21 | Hospitalized covid vs. not hospitalized covid (B1) | 14,480 / 73,191 | Mixed | M and F | 13.50M | 836 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 06.07.21 | Hospitalized covid vs. population (B2) | 24,274 / 2,061,529 | Mixed | M and F | 11.81M | 4732 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 06.07.21 | Covid vs. population (C2) | 112,612 / 2,474,079 | Mixed | M and F | 12.22M | 2263 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 01.07.21 | Very severe respiratory confirmed covid vs. population (A2) | 4,606 / 702,801 | European | M and F | 9.86M | 1057 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | A version of this analysis without UKBB is available on the Covid19-hg website |
| COVID19hg (link) | 01.07.21 | Very severe respiratory confirmed covid vs. population (A2) | 5,870 / 1,155,203 | Mixed | M and F | 7.54M | 1009 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | A version of this analysis without UKBB is available on the Covid19-hg website |
| COVID19hg (link) | 01.07.21 | Hospitalized covid vs. not hospitalized covid (B1) | 4,829 / 11,816 | European | M and F | 8.38M | 319 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | A version of this analysis without UKBB is available on the Covid19-hg website |
| COVID19hg (link) | 01.07.21 | Hospitalized covid vs. not hospitalized covid (B1) | 5,773 / 15,497 | Mixed | M and F | 7.67M | 303 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | A version of this analysis without UKBB is available on the Covid19-hg website |
| COVID19hg (link) | 01.07.21 | Hospitalized covid vs. population (B2) | 9,373 / 1,197,256 | European | M and F | 8.15M | 2794 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | A version of this analysis without UKBB is available on the Covid19-hg website |
| COVID19hg (link) | 01.07.21 | Hospitalized covid vs. population (B2) | 12,888 / 1,295,966 | Mixed | M and F | 7.58M | 3390 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | A version of this analysis without UKBB is available on the Covid19-hg website |
| COVID19hg (link) | 01.07.21 | Covid vs. population (C2) | 29,071 / 1,559,712 | European | M and F | 8.74M | 863 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | A version of this analysis without UKBB is available on the Covid19-hg website |
| COVID19hg (link) | 01.07.21 | Covid vs. population (C2) | 36,590 / 1,668,938 | Mixed | M and F | 8.17M | 885 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | A version of this analysis without UKBB is available on the Covid19-hg website |
| Ellinghaus et al (link) | 06.17.20 | Covid-19 cases with respiratory failure vs Healthy controls | 1,610 / 2,205 | European | M and F | 8.58 M | 391 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | GWAS adjusted for 10 PCs; Tops were lifted to hg19 |
| Ellinghaus et al (link) | 06.17.20 | Covid-19 cases with respiratory failure vs Healthy controls | 1,610 / 2,205 | European | M and F | 8.58 M | 317 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | GWAS adjusted for 10 PCs + age + sex; Tops were lifted to hg19 |
| COVID19hg (link) | 10.20.20 | Very severe respiratory confirmed covid vs. not hospitalized covid (A1) | 269 / 688 | Mixed | M and F | 9.30M | 81 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 10.20.20 | Very severe respiratory confirmed covid vs. population (A2) | 4,336 / 623,902 | Mixed | M and F | 11.83M | 949 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | These results do not include the 23andMe study. A limited version including 23andMe is available on the Covid19-hg website |
| COVID19hg (link) | 10.20.20 | Hospitalized covid vs. not hospitalized covid (B1) | 2,430 / 8,478 | Mixed | M and F | 14.90M | 368 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 10.20.20 | Hospitalized covid vs. population (B2) | 6,406 / 902,088 | European | M and F | 9.87M | 2394 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 10.20.20 | Hospitalized covid vs. population (B2) | 7,885 / 961,804 | Mixed | M and F | 11.43M | 2748 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | These results do not include the 23andMe study. A limited version including 23andMe is available on the Covid19-hg website |
| COVID19hg (link) | 10.20.20 | Covid vs. lab/self-reported negative (C1) | 11,085 / 116,794 | Mixed | M and F | 13.06M | 224 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | These results do not include the 23andMe study. A limited version including 23andMe is available on the Covid19-hg website |
| COVID19hg (link) | 10.20.20 | Covid vs. population (C2) | 14,134 / 1,284,876 | European | M and F | 11.58M | 541 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 10.20.20 | Covid vs. population (C2) | 17,965 / 1,370,547 | Mixed | M and F | 12.71M | 396 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | These results do not include the 23andMe study. A limited version including 23andMe is available on the Covid19-hg website |
| COVID19hg (link) | 10.20.20 | Predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (D1) | 3,204 / 35,728 | Mixed | M and F | 11.48M | 88 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 09.30.20 | Very severe respiratory confirmed vs. population (A2 alpha) | 2,972 / 284,472 | Mixed | M and F | 12.82M | 886 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 09.30.20 | Hospitalized covid vs. Not hospitalized covid (B1 alpha) | 1,389 / 5,879 | Mixed | M and F | 9.47M | 66 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 09.30.20 | Hospitalized covid vs. Population (B2 alpha) | 6,492 / 1,012,809 | Mixed | M and F | 10.53M | 978 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 09.30.20 | Covid vs. Lab/self-reported negative (C1 alpha) | 11,181 / 116,456 | Mixed | M and F | 13.91M | 247 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 09.30.20 | Covid vs. Population (C2 alpha) | 17,607 / 1,345,334 | Mixed | M and F | 13.06M | 476 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hg (link) | 09.30.20 | Predicted covid from self-reported symptoms vs. Predicted or self-reported non-covid (D1 alpha) | 1,777 / 18,895 | Mixed | M and F | 13.82M | 106 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hgi (link) | 06.26.20 | Positive with severe respiratory vs. Population | 536 / 329,391 | Mixed | M and F | 9.31 M | 60 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Tops were lifted to hg19 |
| COVID19hgi (link) | 06.26.20 | Positive Hospitalized vs. Positive Non Hospitalized | 928 / 2,028 | European | M and F | 12.03 M | 130 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Tops were lifted to hg19 |
| COVID19hgi (link) | 06.26.20 | Positive Hospitalized vs. Population | 3,199 / 897,488 | Mixed | M and F | 15.39 M | 453 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Tops were lifted to hg19 |
| COVID19hgi (link) | 06.26.20 | Positive vs. Lab/self reported Negative | 3,523 / 36,634 | Mixed | M and F | 22.04 M | 153 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Tops were lifted to hg19 |
| COVID19hgi (link) | 06.26.20 | Positive vs. Population | 6,696 / 1,073,072 | Mixed | M and F | 20.59 M | 377 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Tops were lifted to hg19 |
| COVID19hgi (link) | 06.26.20 | Positive (predict/self report) vs. Negative (predict/self report) | 1,865 / 29,174 | European | M and F | 12.27 M | 169 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Tops were lifted to hg19 |
| COVID19hgi (link) | 05.13.20 | Positive Hospitalized vs. Positive Non Hospitalized | 716 / 616 | Mixed | M and F | 10.98 M | 958 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hgi (link) | 05.13.20 | Positive vs. Population | 1,678 / 674,635 | Mixed | M and F | 34.01 M | 3,262 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COVID19hgi (link) | 05.13.20 | Positive (predict/self report) vs. Negative (predict/self report) | 1,294 / 26,969 | European | M and F | 7.52 M | 544 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| GENOMICC(link) | 12.11.20 | Positive and critically ill vs. Population | 1,676 / 8,280 | European | M and F | 4.4M | 650 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Number of cases and controls inferred from the article |
| GENOMICC(link) | 12.11.20 | Positive and critically ill vs. Population | 237 / 1,185 | South Asian | M and F | 3.1M | 1035 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Number of cases and controls inferred from the article |
| GENOMICC(link) | 12.11.20 | Positive and critically ill vs. Population | 182 / 910 | African | M and F | 2.9M | 261 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Number of cases and controls inferred from the article |
| GENOMICC(link) | 12.11.20 | Positive and critically ill vs. Population | 149 / 745 | East Asian | M and F | 2.6M | 235 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | Number of cases and controls inferred from the article |
| COLCORONA (link) | 05.25.21 | Time to end of COVID-19 symptoms in colchicine arm | 872 | European | M and F | 6.38M | 86 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COLCORONA (link) | 05.25.21 | Time to end of COVID-19 symptoms in placebo arm | 851 | European | M and F | 6.38M | 153 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COLCORONA (link) | 05.25.21 | Hospitalisation for COVID-19 in colchicine + placebo arms | 58 / 1,797 | European | M and F | 6.38M | 146 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COLCORONA (link) | 05.25.21 | Time to end of COVID-19 symptoms in colchicine + placebo arms | 1723 | European | M and F | 6.38M | 99 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COLCORONA (link) | 05.25.21 | Time to end of COVID-19 symptoms in males in colchicine + placebo arms | 740 | European | M | 6.38M | 113 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb | |
| COLCORONA (link) | 05.25.21 | Time to end of COVID-19 symptoms in females in colchicine + placebo arms | 983 | European | F | 6.38M | 49 | Summary Stats | Annotated | Grasp | EBI | GTeX | eQLdb |
This work was supported by the NHLBI Intramural Research program and the NIH Biowulf high performance computing cluster (https://hpc.nih.gov/).